Another recent study analyzed the gene expression profiles and overall survival rates of melanoma patients with different genotypes treated with ICI and found that an increase in IL-17 GES in melanoma at the baseline of treatment was associated with an improved anti-tumor response to dual ICI therapy, but not related to monotherapy with anti-PD-1 or anti-CTLA-4 ICI (226). This evidence concerns the gene CTLA4 and neoplasm.